Managing NAFLD/NASH in People with T2 Diabetes: Disease Burden • Diagnosis • Current & Emerging Armamentarium
June 24 from 5:30 am — 7:45 am PDT
Supported By: Madrigal Pharmaceuticals
Program Description
This CME/CEU/CPE symposium will focus on risk of nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH) & associated liver fibrosis in people with T2 diabetes, and includes summaries of ADA and other Guidelines on screening, diagnosis, current treatment practice, as well as presentation of novel Phase III data. Clinical Cases will illustrate management of patients with mild/moderate/severe NASH, and your queries will be addressed during a robust Q&A session.
Speakers
Juan Pablo Frias MD
Velocity Clinical Research
Medical Director
Principal Investigator
Los Angeles, CA
Davida F. Kruger MSN, APN-BC, BC-ADM
New Center One
Henry Ford Health System
Division of Endocrinology, Diabetes, Bone and Mineral Disease
Certified Nurse Practitioner
Detroit, MI
Kenneth Cusi MD, FACP, FACE
University of Florida
Department of Medicine
Professor of Medicine
Division of Endocrinology
Diabetes and Metabolism
Gainesville, FL
Michael Roden Prof, MD
CEO of the German Diabetes Center
University Hospital Düsseldorf
Heinrich-Heine University
Department of Endocrinology and Diabetology
Director
Chair/Professor of Endocrinology and Metabolic Diseases
Dusseldorf, Germany